

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The ongoing Phase III DESTINY-BTC01 study compares trastuzumab deruxtecan (T-DXd) alone or in combination with which of the following agents to standard treatment as first-line therapy for patients with advanced HER2-expressing biliary tract cancer (BTC)?
 - a. T-DM1
 - b. Trastuzumab/pertuzumab
 - c. Rilvegostomig
 - d. Zanidatamab
2. The Phase III DESTINY-Gastric04 study of T-DXd versus ramucirumab/paclitaxel for previously treated HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma reported what finding at the interim analysis?
 - a. Inferior overall survival (OS) outcomes with T-DXd
 - b. A nonsignificant trend toward OS improvement with T-DXd
 - c. A statistically significant improvement in OS with T-DXd
 - d. No efficacy findings have been reported yet
3. The bispecific antibody zanidatamab binds to which of the following targets?
 - a. HER2 and CD8
 - b. HER2 and HER3
 - c. HER2 and FGFR2
 - d. Two distinct HER2 domains
4. Which of the following adverse events was most commonly observed in patients receiving zanidatamab for previously treated HER2-amplified BTC?
 - a. Headache
 - b. Blurred vision
 - c. Dry mouth
 - d. Diarrhea
5. What was the approximate objective response rate observed with T-DXd for patients with previously treated HER2 IHC 3+ advanced BTC in the Phase II DESTINY-PanTumor02 trial?
 - a. 0%
 - b. 18%
 - c. 32%
 - d. 56%